SPDYE21

Across TCGA pan-cancer cohorts, SPDYE21 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated SPDYE21 data layer.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SPDYE21 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated SPDYE21 expression acts as an unfavorable survival marker, although some lineages such as DLBC and BRCA show a favorable association.

DLBC, BRCA, and COAD are the cancer types where SPDYE21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Tertile	All	0.801	0.263	<.001	75	view →
BRCA	OS	Tertile	III,IV	0.911	0.762	.002	63	view →
COAD	DFS	Tertile	All	0.423	0.623	.001	61	view →
LUSC	OS	Tertile	II,III,IV	0.216	0.553	<.001	37	view →
LUAD	DFS	Quartile	II,III,IV	0.779	0.600	.004	31	view →
LGG	OS	Median	All	0.747	0.869	<.001	30	view →
GBM	OS	Median	All	0.213	0.320	.003	24	view →
ACC	OS	Median	IV	0.777	0.309	.019	16	view →
KIRP	DFS	Quartile	All	0.626	0.919	.004	16	view →
ESCA	DFS	Quartile	III,IV	0.512	0.217	.006	16	view →
THCA	OS	Median	II,III,IV	1.000	0.818	.008	14	view →
KICH	DFS	Median	All	0.813	0.970	.026	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

SPDYE21–DLBC (DFS)

Open the DLBC breakdown →